LucidScope
AI is already answering questions about your brand. LucidScope shows you what it’s saying, and why.
LucidScope evaluates how leading AI systems respond to real-world questions about your company, products, indications, and competitors.
It maps visibility and positioning in AI-generated answers, traces the sources shaping those answers, and highlights gaps where evidence is missing, outdated, or misrepresented.
What you can do with LucidScope:
-
Perception Mapping: Compare how AI positions your brand versus key competitors.
- See how AI frames your brand versus competitors, by theme and attribute.
-
Answers Mapping: See how models answer the same stakeholder questions, and where they diverge.
- View side-by-side model answers to your key questions, with differences highlighted.
-
Source Tracing: Identify which websites and documents are shaping AI answers, and where to intervene.
- Understand which domains and documents drive the answers, and what’s missing.
-
Launch and campaign monitoring: Track changes over time across models, markets, and topics.
- Monitor shifts in positioning, key claims, and cited sources (you vs competitors).
LucidScope is part of LucidQuest’s intelligence stack, complementing our primary research, conference coverage, and wargaming capabilities.
Combined with NexusBrain (nexusbrain.io), LucidScope insights can be mapped alongside your team’s own field observations to give a complete picture of how AI is shaping your brand’s perception.
Want to see what AI is saying about your brand? Request an AI Answer Audit.
You’ll receive a short report covering Perception, Answers, Source Tracing, and Zero-click gaps.
Already evaluating tools? Test LucidScope.
Questions or feedback? Email us anytime.
December 26, 2025
Respiratory 2025 Review: From Symptom Control to Disease Modification
December 26, 2025
Vaccines 2025 Review: From Emergency Platforms to Durable Public Health Assets
December 25, 2025
Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B
December 25, 2025
Cell and Gene Therapy 2025 Review: Acceleration, Accountability, and the Fight for Scalability
December 24, 2025
Neuroscience 2025 Review: Disease Modification Meets Deliverability
December 24, 2025
Women’s Health 2025 Review: From Fragmented Care to Scaled Platforms
December 23, 2025
Obesity Review 2025: The Rise of Oralization, the Muscle Question, and a New Era of Access Pressure
December 22, 2025
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal
December 22, 2025